One Treatment to End Sickle Cell Pain Crises Passed Its Big Test, Its Maker Says

Beam says its base-editing therapy risto-cel met its main goal, freedom from severe pain crises, in 31 patients at 12 months (company claim, secondary report; rates and safety figures not yet seen). FDA filing as soon as end-2026.

TL;DR

Sickle cell disease's worst moments are its pain crises, when misshapen blood cells block blood vessels and send people to the hospital. Beam Therapeutics says its one-time treatment, risto-cel, did what its trial set out to do: keep patients free of severe pain crises. The therapy uses a base editor, a tool that changes a single letter of DNA without cutting the strand, on a patient's own blood stem cells. The result covers 31 patients followed for 12 months, and hospital stays tied to the crises fell, according to BioPharma Dive's report of the company's announcement; the exact rates and safety figures have not been released yet. It is the first positive late-stage result for base editing, and Beam plans to ask the FDA for approval as soon as the end of 2026. Our odds that the FDA approves it by 2028: 55%. To see the full odds and the timeline of breakthroughs that leads to a one-time fix for sickle cell, subscribe.

Below the line, for paid subscribers: The full story: where it stands, how we got here and what's dated next; our labeled speculation on what it adds up to; and every source.